## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.35 indicates fundamental undervaluation. Quality metrics strong (ROE 18%). Caution: momentum weakening (-4.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($305.56)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Can UNH's AI-Powered Virtual Assistance Enhance Member Experience?**
- Source: TradingView | 20251208T160808 | Neutral | Relevance: 99%
-  UnitedHealth Group (UNH) is integrating AI-powered virtual assistance to improve member experience by streamlining benefit navigation and healthcare choices. This initiative aims to automate routine tasks like checking claim status and finding in-network doctors, reducing call-center load and enhancing digital engagement. Competitors like Elevance Health and Humana are also expanding their AI healthcare solutions to offer more intuitive and personalized member interactions.

**2. UnitedHealth Group Incorporated $UNH Shares Sold by Fayez Sarofim & Co**
- Source: MarketBeat | 20251209T102446 | Neutral | Relevance: 99%
-  Fayez Sarofim & Co reduced its stake in UnitedHealth Group Incorporated by 4.1% in the second quarter, selling 47,778 shares but still owning 1,115,813 shares worth $350.12 million. Despite this, other institutional investors increased their holdings, and analysts maintain a "Hold" consensus rating with a target price of $385.54 for UNH, which recently declared a quarterly dividend of $2.21 per share.

**3. SVB Wealth LLC Sells 4,770 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251208T122946 | Neutral | Relevance: 99%
- SVB Wealth LLC has reduced its stake in UnitedHealth Group Incorporated (NYSE:UNH) by selling 4,770 shares, bringing its total holdings to 17,725 shares valued at $5.53 million. This comes as UnitedHealth beat EPS estimates with $2.92 and reported $113.16 billion in revenue, also announcing a quarterly dividend of $2.21. The stock, largely institutionally held, has a mixed analyst consensus of "Hold" with an average target price of $385.54.

**4. Gabelli Funds LLC Lowers Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251209T094520 | Somewhat-Bullish | Relevance: 98%
-  Gabelli Funds LLC reduced its stake in UnitedHealth Group (NYSE:UNH) by 24.7% in the second quarter, selling 9,570 shares and ending with 29,170 shares valued at $9.1 million. Despite this reduction, other institutional investors either increased their holdings or initiated new positions. The company recently reported strong quarterly earnings, beating EPS estimates, and declared a quarterly dividend of $2.21 per share.

**5. Shepherd Financial Partners LLC Cuts Stake in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251207T113356 | Neutral | Relevance: 98%
-  Shepherd Financial Partners LLC significantly reduced its stake in UnitedHealth Group (NYSE:UNH) by 76.5% during the second quarter, selling over 4,400 shares and retaining 1,368 shares valued at $427,000. UnitedHealth Group reported strong Q2 earnings of $2.92 per share, exceeding expectations, with revenues up 12.2% year-over-year. The company also declared a quarterly dividend of $2.21 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 23 ($0.00M) |
| Sells | 1 ($0.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 10.2% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.35 suggests fair value with growth premium. Forward P/E 18.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $293.1B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.35 |
| Forward P/E | 18.3 |
| Current P/E | 19.8 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.2% to -2.4% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. MACD histogram positive (1.25), confirming momentum. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.44% (CS: 40) | Weak |
| RSI_14 | 45.2 | Neutral |
| MACD Histogram | 1.25 | Bullish |
| vs SMA20 | 0.996x | Below |
| vs SMA50 | 0.948x | Below |
| vs SMA200 | 0.898x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $323.60
- **Stop Loss:** $305.56 (5.6% risk)
- **Target:** $359.68 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 16
- **Position Value:** $5,177.60
- **Portfolio %:** 5.18%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*